Merck & Co Inc (NYSE:MRK) recently received regulatory approval for Winrevair (sotatercept), a groundbreaking therapy for adults with pulmonary arterial hypertension (PAH). This approval marks a ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S.

The Food and Drug Administration approved Winrevair last week. The drug is indicated for a rare and deadly cardiovascular disorder called pulmonary arterial hypertension. PAH has long been challenging ...

The US Food and Drug Administration has approved the injectable biologic sotatercept-csrk (Winrevair) for the management of adults with pulmonary arterial hypertension (PAH), drugmaker Merck announced ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ ...

The Food and Drug Administration has approved Merck’s Winrevair (sotatercept-csrk) injection, 45 mg, 60 mg, for the treatment of adults with pulmonary arterial hypertension to increase exercise ...

The U.S. Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults. The FDA previously granted Winrevair a ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Credit: Merck. Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands. The Food and Drug Administration ...

Merck & Co. Inc. (NYSE:MRK) announced results Tuesday from its Phase 3 HYPERION trial evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...